艾伯维2025H1:自免双子星116亿美元,FRα ADC增长76%

医药魔方
Aug 01, 2025

7月31日,艾伯维公布了2025H1业绩,上半年总营收287.66亿美元,同比增长7.4%。自免、神经科学、肿瘤、美容以及眼科各大业务分别带来138.95亿美元(+12.6%)、49.65亿美元(+20.3%)、33.09亿美元(+4.2%)、23.81亿美元(-9.8%)、10.20亿美元(-4.8%)的收入。自免领域,IL-23单抗Skyrizi(利生奇珠单抗)和JAK1抑制剂Rinvoq(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10